Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-05
2011-07-05
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07973029
ABSTRACT:
Provided is a method of treating the health-related quality-of-life (HRQOL) symptoms of a lung disease, comprising the administration of an inhalable aerosol of aztreonam lysine. The method is suitable for the short term and sustainable long term treatment of HRQOL symptoms.
REFERENCES:
patent: 5152456 (1992-10-01), Ross et al.
patent: 5261601 (1993-11-01), Ross et al.
patent: 5518179 (1996-05-01), Humberstone et al.
patent: 6660249 (2003-12-01), Montgomery
patent: 6962151 (2005-11-01), Knoch et al.
patent: 6983747 (2006-01-01), Gallem et al.
patent: 7138419 (2006-11-01), Montgomery et al.
patent: 7208141 (2007-04-01), Montgomery
patent: 7214364 (2007-05-01), Montgomery
patent: 7427633 (2008-09-01), Montgomery
patent: 2007/0185076 (2007-08-01), Montgomery
patent: 2008/0050439 (2008-02-01), Montgomery
patent: WO-01/34232 (2001-05-01), None
patent: WO-2005/007132 (2005-01-01), None
Am. J. Respir. Crit. Care Med. (1995) “Standardization of Spirometry” 152: 1107-1136.
Burns, J. et al. (1998) “Microbiology of Sputm from Patients at Cystic Fibrosis Centers in the US” Clin Infect Dis. 27:158-163.
Chang, J. et al. (1999) “Assessment of Health-Related Quality of Life in Patients with Interstitial Lung Disease” Chest 116(5) 1175-1182.
Clement, A. et al. (2006) “Long Term Effects of Azithromycin in Patients with Cystic Fibrosis: a Double Blind, Placebo Controlled Trial” Thorax 61:895-902.
Donaldson, S. et al. (2006) “Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline” NEJM 354(3): 241-250.
Elkins, M. et al. (2006) “A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis” NEJM 354(3): 229-240.
Fuchs, H. et al. (1994) “Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis” NEJM 331(10): 637-642.
Gibson, R. et al. (2003) “Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis” Am J Respir Crit Care Med 168: 918-951.
Gibson, R. et al. (2006) “Microbiology, Safety and Pharmacokinetics of Aztreonam Lysinate for Inhalation in Patients with Cystic Fibrosis” Ped Pulm 41:656-665.
Gilead Press Release (2006) “Gilead Announces Preliminary Results from Phase III Study of Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis”.
Gilead Press Release (2007) “Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis”.
Goss, C. and Quittner, A. (2007) “Patient-reported Outcomes in Cystic Fibrosis” Proc Am Thorac Soc. 4:378-386.
Guyatt, G. (2000) “Making Sense of Quality-of-Life Data” Med. Care 38(9) Suppl II:175-179.
Henry, B. et al. (2003) “Development of the Cystic Fibrosis Questionnaire (CGQ) for Assessing Quality of Life in Pediatric and Adult Patients” Qual Life Res 12: 63-76.
Hodson, M. et al. (2002) “A Randomised Clinical Trial of Nebulised Tobramycin or Colistin in Cystic Ribrosis” Eur Respir. J. 20:658-664.
Jaeschke, R. et al. (1989) “Ascertaining the Minimal Clinically Important Difference” Controlled Clin Trials 10:407-415.
Juniper, E. et al. (1993) “Measuring Quality of Life in Asthma” Am Rev Respir Dis 147:832-838.
Knudson, R. et al. (1983) “Changes in the Normal Maximal Expiratory Flow-Volume curve with Growth and Aging” 127: 725-734.
Lamb and Goa (1999) “Management of Patients with Cystic Fibrosis” Dis Manage Health Outcomes 6(2): 93-108.
McCoy, K. et al. (2007) “Aztreonam Lysine for Inhalation (AZLI) for CF Patients withP. aeruginosa(PA) Infection” Eur CFC Poster No. 40.
McCoy, K. et al. (2008) “Inhaled Aztreonam Lysine for Chronic AirwayPseudomonas aeruginosain Cystic Fibrosis” Am J Repir Crit Care Med 178:921-928.
Modi, A. and Quittner,A. (2003) “Validation of a Disease-specific Measure of Health-Related Quality of Life for Children with Cystic Fibrosis” J Ped Psych 28(7): 535-546.
Modi,A. et al. (2005) “Multi-method Measurement of Treatment Adherence for Children with Cystic Fibrosis and Its Relationship to Health-related Quality of Life” Pediatric Pulmon S28:371.
Moss,R. (2001) “Administration of Aerosolized Antibiotics in Cystic Fibrosis Patients” Chest 120(3) Suppl. 107S.
Moss,R. (2002) “Long-Term Benefits of Inhaled Tobramycin in Adolescent Patients with Cystic Fibrosis” Chest 121(1): 55-63.
Prescribing Information (2001) TOBI.
Quittner and Buu (2002) “Effects of Tobramycin Solution for Inhalation on Global Ratings of Quality of Life in Patients with Cystic Fibrosis andPseudomonas aeruginosaInfection” Ped. Pul. 33:269-276.
Quittner, A. et al. (2005) “Development and Validation of the Cystic Fibrosis Questionnaire in the US: A Health-related Quality-of-life Measure for Cystic Fibrosis” Chest 128(4): 2347-2354.
Ramsey, B. et al. (1993) “Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis” NEJM 328(24): 1740-1746.
Ramsey,B et al. (1999) “Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis” NEJM 340(1): 23-30.
Rosenfeld,M. et al. (2001) “Defining a Pulmonary Exacerbation in Cystic Fibrosis” J Ped 139(3): 359-365.
Smith, A. et al. (1989) “Safety of Aerosol Tobramycin Administration for 3 Months to Patients with Cystic Fibrosis” Ped. Pulm. 7:265-271.
International Search Report and Written Opinion for PCT/US2008/076431, Intl Filing Date Sep. 15, 2008/ mailed Dec. 9, 2008.
Business Wire (2010) “Gilead's Head-to-Head Study of Cayston Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-Inferiority,” Jun. 18, 2010.
EP 08836327.0 Communication dated May 3, 2010.
Montgomery Alan B.
Yeager Melissa A.
Gilead Sciences, Inc.
Henley, III Raymond J
Morgan Lorie Ann
LandOfFree
Inhaled aztreonam lysine for the treatment of deficits in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhaled aztreonam lysine for the treatment of deficits in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhaled aztreonam lysine for the treatment of deficits in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681188